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211* Lung clearance index (LCI) as a tool to assess the effect of
antibiotics among preschoolers with cystic ﬁbrosis
E. Hatziagorou1, V. Avramidou1, S. Botskariova1, F. Kirvasillis1, J. Tsanakas1.
1Hippokration Hospital, Aristotle University of Thessaloniki, 3rd Paediatric Dept,
Thessaloniki, Greece
Background: In Cystic Fibrosis (CF) lung function testing is a useful tool for
monitoring progression of lung disease. Studies in CF children have shown that
lung clearance index (LCI) is signiﬁcantly greater than healthy controls.
Aim: The objectives of this study were: (a) To compare LCI among CF preschoolers
(aged 2 to 5 years) and healthy controls and (b) to assess the effect of two-week iv
antibiotic treatment on LCI among CF preschoolers with CF.
Method: Twenty-eight children with CF (20 were infected with Pseudomonas
aeruginosa) and 27 healthy controls performed Multiple-Breath Washout (MBW)
measurements and LCI was assessed. The ones with Ps. aeruginosa infection were
measured again one month following a two-week course of iv antibiotics.
Results: Children with CF had signiﬁcantly higher LCI compared to controls
(mean difference for CF vs control [95%CI] 2.6 [1.8, 3.7], p< 0.001). Children
with CF who were infected with Ps. aeruginosa had signiﬁcantly higher LCI,
when compared with Ps. Negative CF children (mean difference [95%CI]: 1.75
[0.38, 3.5], p< 0.05). LCI was reduced signiﬁcantly after two-weeks course of iv
antibiotics (mean difference [95%CI]: −1.97 [1.2, 3.6], p< 0.001).
Conclusions: LCI is a sensitive marker to detect lung function abnormalities among
preschoolers with CF. It can be used to assess severity of the disease and the effect
of treatment.
212 Cystic ﬁbrosis (CF) adult patients and nebulized treatments:
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Objectives: To evaluate the adherence level, the knowledges of cystic ﬁbrosis (CF)
adult patients and their physicians about nebulized treatments.
Methods: A self-administered anonymous questionnaire was given to 199 CF adults
followed-up in 13 CF Care Centres and to 1 physician of each centre. Questions
concerned the characteristics of the patients and their nebulized treatments used at
home.
199 patients’ questionnaires and 10 physicians’s questionnaires returned (76% of
the expected theorical headcount). The mean age of the patients (49.5% males)
was 28 years old. 65% of patients considered that their illness was a modered
disease. 86% received nebulizations. Patients self-reported a mild adherence to
daily treatment (50%). Up to 70% used treatment more than 3 days/week. Most of
patients felt that they were well informed about the illness, their nebulizers’ system,
cleaning and disinfection process. Nevertheless, treatment mechanisms were not
wellknown; 72% of patients washed their nebulizer every day; 17% disinfected
without washing; 48% disinfected it every day; 15% never disinfected their system.
Physicians didn’t considered nebulizations as easy treatments, and overestimated
patients’ adherence. Advices to disinfection were heterogeneous.
Conclusion: This study conﬁrms the need for clear, written and oral, unvarying
informations with an adequate education explaining the purpose of each treatment
and a regular evaluation of knowledges and practices.
213 Optimization of inhalation treatment − assessment of the
inﬂuence of diluent and air humidity on particle distribution of
colistin administered by pneumodosimeter NEBSTEER®
Z. Podolec1, J. Siekaniec1. 1CBR MEDiNET, Dept. of Aerosology and Aerosol
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Introduction: Inhalations with colistin (Polfa PL) are used in treatment of chronic
respiratory infections caused by cystic ﬁbrosis and bronchiectasis.
The aim of the study was to assess the inﬂuence of air humidity on the quality of
aerosol produced by system for breath control administration of aerosol by BCTS
(Bronchial Control Treatment System) method.
Method: The system included Sidestream® ventilated nebulizer (Respironics New
Jersey, Inc. USA), Porta-neb® compressor (Respironics New Jersey, Inc. USA),
and NEBSTEER® pneumodosimeter (abcMED PL). Aerosol’s particle size was
measured using three different solutions of colistin (40mg) dissolved in 4ml of:
NaCl 0.9%; NaCl 0.45% and Aqua p.i. The effect of diluent and air humidity on
the aerosol particles distribution was measured by laser diffraction method using
Autocounter (Malvern GB).
Results: MMAD values of colistin aerosol for air humidity of 30%, 60%, 90%
equaled to: for NaCl 0.9%: 4.04, 3.28 and 3.27 mm; for NaCl 0.45%: 3.71, 3.26
and 3.63mm and for Aqua p.i.: 4.34 3.59 and 3.18mm respectively. Our study
demonstrated statistically signiﬁcant inﬂuence (p< 0.05) of air humidity and diluent
on the aerosol particle size of colistin.
Conclusion: In order to optimize inhalation treatment and obtaining maximum
deposition in the peripheral part of the respiratory system irrespective of the degree
of obstruction and the occurrence of bronchial deformation, it is recommended to
pay attention to the composition of the solution and environmental conditions.
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Introduction: Aerosol delivery of therapies is a cornerstone of the management of
cystic ﬁbrosis airways disease. Recent developments in nebuliser technology have
enabled adaptive aerosol delivery of mesh generated aerosol particles. We have
previously explored in a RCT, a further modiﬁcation of this technology. Target
Inhalation Mode (TIM) optimises patient inhalations through a direct feedback
mechanism. We demonstrated a reduction in treatment delivery times using TIM
as compared to the standard Tidal Breathing Mode (TBM). Following this study
we have evaluated TIM treatment times and adherence during an open follow-up
phase.
Methods: Twenty patients had a baseline period on TBM after which they were
randomised to TBM or TIM. At the end of the study all patients were changed to
TIM. In this study, treatment times and adherence were compared in the baseline
period on TBM to those in the follow-up period on TIM.
Results: Data showed that mean (SD) treatment times reduced from 6.4(3.2)min
to 3.0(1.8)min following change to TIM (P = 0.005). Adherence was maintained
[baseline period: 84(14)%; follow up period 83(18)%]. All patients preferred TIM
to TBM.
Conclusion: TIM reduces nebuliser treatment times and adherence appears to be
maintained, although longer duration studies are required to examine this.
